News | October 30, 2022
Granules India plans H2 FY 2022-23 R&D spend in Rs. 80-90 Cr
The company's long-term strategy is on science, technology and innovation and the company's strategy relating to this is on track
The company's long-term strategy is on science, technology and innovation and the company's strategy relating to this is on track
Gland Pharma Q2 FY2023 consolidated net profit up at Rs. 241.24 Cr
Ketorolac Tromethamine Tablets are indicated to relieve moderately severe pain, usually after surgery.
The CRL did not identify any outstanding scientific issues with the product.
Submission based on QuANTUM-First results showing quizartinib plus chemotherapy significantly improved overall survival compared to chemotherapy alone
Pluvicto and Scemblix launches are progressing well and we are awaiting data in earlier lines of therapy.
Micafungin for Injection had annual sales of US $99 million in the United States according to IQVIA data
The company has received the Certificate of GMP Compliance from the representative European inspection authority, Health Products Regulatory Authority (HPRA), Ireland.
A MoU was signed between Ministry of Ayush and Ministry of Tribal Affairs to collaborate in Ayush sector
Separate Phase 3 study evaluating 200 days of therapy with PREVYMIS in HSCT recipients at high risk of late clinically significant CMV infection recently completed, meeting its primary endpoint
Subscribe To Our Newsletter & Stay Updated
